R&D Clinical Trials Round-Up – Jan to Feb 2026 Read how Jan-Feb '26 offered a revealing cross-section of how R&D is evolving across therapy areas.
R&D AI in clinical development & ‘white space’, with Andrew McKi... Andrew McKinnon, senior vice president and executive general manager at Medable, discussesleveraging AI to transform & accelerate clinical development
R&D Rare disease at an inflection point: Why the next wave will ... As rare disease becomes more competitive, information parity is disappearing.
R&D Net Treatment Benefit in rare disease trials: Aligning trial... Net Treatment Benefit provides a formal framework to integrate multiple prioritised outcomes into a single measure of overall treatment effect.
R&D How innovative trial approaches are advancing rare disease r... Innovative trial designs that harness data augmentation, RWD, and the power of AI are enabling a new era of rare disease research.
R&D Agentic AI and the human element: Building trustworthy autom... The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.
News Lilly unveils employer scheme for weight-loss drug Zepbound Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
